- “Noltec tab”(Ilaprazole), the nation’s first PPI agent and the 14th new indigenous drug - “Noltec tab” is a PPI(Proton Pump Inhibitor) agent and underwent the multinational clinical trial, and was launched in Korea after its first debut in China. - Registered the substance patent globally in the United States, EU, China, Japan, etc., acquiring the intellectual property right - The market share and sales are expected to increase on the back of the addition of the indication for reflux esophagitis.

SUPECT(API: Radotinib) is Asia’s 1st Chronic Myeloid Leukemia (CML) treatment which solely developed by technicians of IL-YANG Pharm. “SUPECT” had obtained its material patent in US, Canada, New Zealand, Australia, Singapore, Indonesia, Malaysia, Mexico, Vietnam, EURASIA (9 notions including Russia) and etc.

Full-fledged operation of control tower for vaccine development in various fields Top priority is to export the vaccines to countries with low vaccine availability, as well as Korea

Designated as the research target of TEPIK(Transgovernmental Enterprise for Pandemic Influenza in Korea)

IL-YANG Pharmaceutical developed the cytokine material that has a market worth in excess of approximately $65 billion and launched 4 types of research reagents.